J. Porter

P. Coleridge-Smith, J. Scurr, J. Porter, 1999, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method.

P. Brissot, D. Guyader, O. Loréal, 2000, Journal of hepatology.

Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin.

P. Brissot, O. Loréal, R. Hider, 1999, Analytical biochemistry.

Endothelial activation in patients with chronic venous disease.

J. Scurr, D. Shields, P. C. Smith, 1998, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

E. Neufeld, S. Perrotta, M. Cappellini, 2020, The New England journal of medicine.

Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.

T. S. St. Pierre, D. Weatherall, N. Olivieri, 2015, Blood.

Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload

D. Nathan, A. Taher, J. Porter, 2007 .

One‐year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation

M. Cappellini, A. Inati, A. Taher, 2017, Pediatric blood & cancer.

Deferoxamine pharmacokinetics.

J. Porter, 2001, Seminars in hematology.

Psychosocial and clinical burden of thalassaemia intermedia and its implications for prenatal diagnosis.

D. Skuse, A. Yardumian, J. Porter, 1995, Archives of disease in childhood.

Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension

E. Neufeld, F. Trachtenberg, E. Vichinsky, 2013, Haematologica.

Sildenafil therapy in thalassemia patients with doppler-defined risk for pulmonary hypertension Running heads : Sildenafil therapy in thalassemia

F. Trachtenberg, V. Sachdev, A. Taher, 2013 .

Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β‐thalassaemia presenting with osteopenia‐osteoporosis syndrome

Farrukh T Shah, R. Bajoria, R. Chatterjee, 2012, British journal of haematology.

11 The toxic effects of desferrioxamine

E. Huehns, J. Porter, 1989 .

Results of long term iron chelation treatment with deferoxamine.

J. Porter, B. Davis, 2002, Advances in experimental medicine and biology.

Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias

B. Kaya, S. Pancham, Farrukh T Shah, 2021, British journal of haematology.

Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease

S. K. White, S. Piechnik, P. Elliott, 2013, Journal of Cardiovascular Magnetic Resonance.

Cytotoxicity and Apoptogenic Activity of A Novel Synthetic Iron Chelator 1-(N-Acetyl-6-Aminohexyl)-3-Hydroxy-2-Methylpyridin-4-One (CM1) In Human Leukemic Cells

S. Fucharoen, Nittaya Chansiw, J. Porter, 2013 .

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.

J. Cleveland, J. Porter, K. Maclean, 2001, Blood.

HPLC determination of 1,2-diethyl-3-hydroxypyridin-4-one (CP94), its iron complex [Fe(III) (CP94)3] and glucuronide conjugate [CP94-GLUC] in serum and urine of thalassaemic patients.

R. Hider, S. Singh, J. Porter, 1994, Journal of pharmaceutical and biomedical analysis.

Optimizing iron chelation strategies in beta-thalassaemia major.

J. Porter, 2009, Blood reviews.

Anti-Platelet Aggregation and Anti-Cyclooxygenase Activities for a Range of Coffee Extracts (Coffea arabica)

S. Srichairatanakool, S. Fucharoen, I. Mackie, 2020, Molecules.

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade®)

A. Ganser, M. Cappellini, D. Bowden, 2008 .

Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines.

R. Hider, J. Porter, K. P. Hoyes, 1992, Cancer research.

Cell cycle synchronisation by 3-hydroxypyridin-4-one iron chelators

J. Porter, K. P. Hoyes, 1996 .

Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin

R. Hider, J. Porter, M. Garbowski, 2017, Haematologica.

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions

M. Cappellini, V. Viprakasit, A. Taher, 2016, British journal of haematology.

Mechanisms of plasma non‐transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients

Jeffery L. Miller, C. Niemeyer, E. Vichinsky, 2014, British journal of haematology.

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.

M. Cappellini, V. Viprakasit, A. Taher, 2016, Blood cells, molecules & diseases.

Toxicity Study of a Novel Oral Iron Chelator: 1-(N-Acetyl-6-Aminohexyl)-3 Hydroxy-2-Methylpyridin-4-One (CM1) in Transgenic b-Thalassemia Mice

S. Fucharoen, Nittaya Chansiw, J. Porter, 2013 .

Exploring the Clinical Utility of Renal Safety Biomarkers during Iron Chelation Therapy in Patients with β-Thalassemia and Other Anemias

M. Cappellini, F. Dieterle, C. Pallaud, 2017 .

New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

S. Perrotta, A. Taher, A. Kattamis, 2017, American journal of hematology.

Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment

M. Cappellini, V. Viprakasit, Mohsen Saleh Elalfy, 2016, European journal of haematology.

One-year results from a prospective randomized trial comparing phlebotomywith deferasirox for the treatment of iron overload in pediatric patients with thalassemiamajor following curative stem cell transplantation

M. Cappellini, A. Inati, A. Taher, 2016 .

Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study

A. Ganser, Zhi-xiang Shen, Sung-Soo Yoon, 2013, Haematologica.

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

E. Neufeld, J. Boudreaux, E. Vichinsky, 2012, Blood.

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias

S. Thein, A. Taher, G. Forni, 2011, European journal of haematology.

Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial.

A. Ganser, Zhi-xiang Shen, Sung-Soo Yoon, 2010, Blood.

Deferasirox—current knowledge and future challenges

J. Porter, 2010, Annals of the New York Academy of Sciences.

Deferasirox: An Update

J. Porter, 2009, Hemoglobin.

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.

E. Glimm, A. Cohen, J. Porter, 2008, Blood.

Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Commentary

E. Glimm, D. Nathan, A. Cohen, 2008 .

Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.

M. Baccarani, P. Marks, S. Abish, 2005 .

Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic

S. Lugthart, J. Howard, Farrukh T Shah, 2020, British journal of haematology.

Non‐transferrin‐bound iron induced by myeloablative chemotherapy

S. Srichairatanakool, R. Hider, S. Bradley, 1997, British journal of haematology.

Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia.

J. Porter, B. Davis, 2000, Blood.

Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease.

J. Scurr, D. Shields, J. Porter, 1997, Journal of vascular surgery.

2 The development of iron chelating drugs

R. Hider, E. Huehns, J. Porter, 1989 .

The development of iron chelating drugs.

R. Hider, E. Huehns, J. Porter, 1989, Bailliere's clinical haematology.

Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.

D. van der Helm, P. Dobbin, G. Xiao, 1993, Journal of medicinal chemistry.

MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.

J. Porter, P. Eleftheriou, Julie May Glanville, 2006 .

Clinical Evaluation of Deferasirox (Exjade®, ICL670)

J. Porter, 2007 .

A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.

E. Vichinsky, N. Olivieri, A. Piga, 2004 .

Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial

M. Cappellini, A. Taher, A. El‐Beshlawy, 2008 .

Concepts and goals in the management of transfusional iron overload

J. Porter, 2007, American journal of hematology.

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.

R. Hider, B. Psaila, Pimpisid Koonyosying, 2017, Blood.

The challenges of adherence and persistence with iron chelation therapy

A. El‐Beshlawy, J. Porter, M. Evangeli, 2011, International journal of hematology.

thalassemia: a Thalassemia Clinical Research Network report regurgitant jet velocity measured by Doppler-echocardiography in Risk factors and mortality associated with an elevated tricuspid

E. Neufeld, J. Boudreaux, F. Trachtenberg, 2014 .

Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report.

E. Neufeld, J. Boudreaux, F. Trachtenberg, 2011, Blood.

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

E. Neufeld, S. Perrotta, M. Cappellini, 2018, Blood.

Predicting erythroid response to recombinant erythropoietin plus granulocyte colony-stimulating factor therapy following a single subcutaneous bolus in patients with myelodysplasia.

I. Cavill, D. Bowen, M. Groves, 2006, Haematologica.

Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions

E. Vichinsky, A. Kutlar, N. Olivieri, 2008, Transfusion.

Quality of life in thalassemia: A comparison of SF‐36 results from the thalassemia longitudinal cohort to reported literature and the US norms

E. Neufeld, F. Trachtenberg, L. Schilling, 2011, American journal of hematology.

Sudden exertional death in sickle cell trait

S. Walsh, M. Loosemore, J. Porter, 2011, British Journal of Sports Medicine.

Iron chelation adherence to deferoxamine and deferasirox in thalassemia

E. Neufeld, F. Trachtenberg, E. Vichinsky, 2011, American journal of hematology.

Design, synthesis, and evaluation of novel 2-substituted 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators.

R. Hider, R. Kayyali, J. Porter, 2002, Journal of medicinal chemistry.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

D. Pennell, M. Cappellini, Chi-kong Li, 2011, Haematologica.

Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.

D. Pennell, A. Arai, B. Bozkurt, 2013, Circulation.

Combined chelation therapy with deferasirox and deferoxamine in thalassemia.

E. Vichinsky, A. Lal, P. Harmatz, 2013, Blood cells, molecules & diseases.

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

D. Pennell, A. Piga, Yiyun Zhang, 2012 .

A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality

D. Pennell, J. Moon, J. M. Walker, 2010 .

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

J. Eccleston, R. Hider, R. Kayyali, 2010, Translational research : the journal of laboratory and clinical medicine.

Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.

R. Abeysinghe, R. Hider, S. Singh, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Red blood cell-derived microparticles: An overview.

J. Porter, M. Westerman, 2016, Blood cells, molecules & diseases.

Decrement in Cellular Iron and Reactive Oxygen Species, and Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract

S. Srichairatanakool, S. Fucharoen, Pimpisid Koonyosying, 2019, Pancreas.

Long-term Follow-up of Hypothalamic-Pituitary Axis in Thalassaemic Patients with Secondary Amenorrhoea

R. Chatterjee, J. Porter, M. Katz, 1995 .

Prospective study of the hypothalamic‐pituitary axis in thalassaemic patients who developed secondary amenorrhoea

R. Chatterjee, J. Porter, M. Katz, 1993, Clinical endocrinology.

Deferiprone and hepatic fibrosis.

G. Brittenham, D. Weatherall, E. Vichinsky, 2003, Blood.

Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous beta-thalassaemia.

D. Pennell, D. Firmin, L. Anderson, 2000 .

Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy

A. Pizzey, I. Mackie, J. Porter, 2008, British journal of haematology.

Phytosterol, Lipid and Phenolic Composition, and Biological Activities of Guava Seed Oil

S. Srichairatanakool, N. Utama‐ang, C. Uthaipibull, 2020, Molecules.

A novel method of cardiac iron measurement using magnetic resonance T2*imaging in thalassemia: Validation and clinical application

D. Pennell, D. Firmin, L. Anderson, 2000 .

Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

E. Vichinsky, D. Killilea, P. Harmatz, 2006, British journal of haematology.

Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents

B. Davidson, J. Porter, P. Boulos, 2004, European Journal of Nuclear Medicine.

Selective Loss of Anterior Pituitary Volume with Severe Pituitary‐Gonadal Insufficiency in Poorly Compliant Male Thalassemic Patients with Pubertal Arrest

G. Bydder, A. Oatridge, G. Bydder, 1998, Annals of the New York Academy of Sciences.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

S. Perrotta, M. Cappellini, V. Viprakasit, 2022, The Lancet. Haematology.

Effect of automated red cell exchanges on oxygen saturation on-air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome

J. Aneke, J. Porter, N. Huntley, 2016, Nigerian medical journal : journal of the Nigeria Medical Association.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study

M. Cappellini, G. Graziadei, A. Taher, 2018, Haematologica.

Interaction of Transfusion and Iron Chelation in Thalassemias.

J. Porter, M. Garbowski, 2018, Hematology/oncology clinics of North America.

Hemoglobinopathies in Pregnancy

J. Howard, J. Porter, S. Tuck, 2015 .

Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress.

S. Srichairatanakool, S. Fucharoen, J. Porter, 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

Ribonucleotide reductase, lipoxygenase and the intracellular low-molecular-weight iron pool.

C. Cooper, J. Porter, 1997, Biochemical Society transactions.

Liver iron measurement by MRI

J. Porter, 2005 .

Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage

J. Hazell, E. Huehns, J. Porter, 1989, British journal of haematology.

Rapid flow cytometric quantitation of reticulated platelets in whole blood.

I. Mackie, S. Machin, P. Harrison, 1996, Platelets.

Eltrombopag Mobilizes Intracellular Iron Stores at Concentrations Lower Than Those Required with Other Clinically Available Iron Chelators

B. Psaila, J. Porter, M. Sola-Visner, 2014 .

Calibration of Myocardial T2* Values in Post-Mortem Hearts.

D. Pennell, L. Anderson, J. M. Walker, 2005 .

Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice

S. Srichairatanakool, S. Fucharoen, Pimpisid Koonyosying, 2022, Frontiers in Physiology.

Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization

J. Porter, M. Garbowski, Evangelia Vlachodimitropoulou Koumoutsea, 2015, British journal of haematology.

The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase*

C. Cooper, R. Hider, R. Cammack, 1996, The Journal of Biological Chemistry.

Pruritus after administration of hetastarch.

H. J. Williams, J. Porter, N. Leftley, 1982, British medical journal.

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

M. Cappellini, V. Viprakasit, R. Galanello, 2016, European journal of internal medicine.

Low plasma heparin cofactor II levels in thalassaemia syndromes are corrected by chronic blood transfusion

I. Mackie, S. Machin, J. Porter, 1995, British journal of haematology.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

M. Cappellini, V. Viprakasit, A. Taher, 2014, European journal of haematology.

Pharmacokinetics, Metabolism, and Disposition of Deferasirox in β-Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State

G. Bruin, F. Waldmeier, J. Porter, 2010, Drug Metabolism and Disposition.

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

M. Cappellini, Chi-kong Li, S. Thein, 2010, Haematologica.

Sickle cell disorders and chronic intravascular haemolysis are associated with low plasma heparin cofactor II

I. Mackie, J. Porter, S. Machín, 1993, British journal of haematology.

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

E. Neufeld, H. Rienhoff, E. Vichinsky, 2011, Haematologica.

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

Farrukh T Shah, John B Porter, J. Porter, 2010, Hematology/oncology clinics of North America.

Monitoring and treatment of iron overload: state of the art and new approaches.

J. Porter, J B Porter, 2005, Seminars in hematology.

Safety and efficacy of pegylated interferon α-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia

E. Neufeld, E. Vichinsky, M. Jonas, 2008, Haematologica.

Sperm DNA damage in potentially fertile homozygous beta-thalassaemia patients with iron overload.

A. Pizzey, D. Irvine, M. Petrou, 2002, Human reproduction.

Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

D N Firmin, D J Pennell, D. Pennell, 2001, European heart journal.

Facilitated uptake of zinc into human erythrocytes. Relevance to the treatment of sickle-cell anaemia.

P. Taylor, R. Hider, L. Ejim, 1990, Biochemical pharmacology.

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.

Vip Viprakasit, Hugh Young Rienhoff, Paul Harmatz, 2012, Blood.

Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity.

P. Taylor, R. Hider, J. Porter, 1990, Journal of medicinal chemistry.

Platelet labelling with indium-hydroxypyridinone and indium-hydroxypyranone complexes

R. Abeysinghe, R. Hider, J. Porter, 1994, European Journal of Nuclear Medicine.

Iron chelator design.

R. Hider, S. Singh, J. Porter, 1994, Advances in experimental medicine and biology.

Iron chelating agents with clinical potential

R. Hider, J. Porter, S. Singh, 1992 .

6-Alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium

R. Abeysinghe, R. Hider, J. Porter, 1999, European Journal of Nuclear Medicine.

Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia

J. Porter, B. Davis, 2000 .

One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and β-thalassaemia major: potential cure of both marrow disorders

S. Mackinnon, S. Verfuerth, A. Goldstone, 2000, Bone Marrow Transplantation.

Adults with Severe Sickle Cell Anaemia and Iron Overload Have a High Incidence of Osteopenia and Osteoporosis.

Farrukh T Shah, R. Chatterjee, J. Porter, 2004 .

Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera

C. Rapisarda, R. Hider, R. Cammack, 2007, JBIC Journal of Biological Inorganic Chemistry.

Contrasting interspecies efficacy and toxicology of 1, 2 ‐diethy 1–3 ‐hydroxypyridin‐4‐one, CP9 4, relates to differing metabolism of the iron chelating site

G. Brittenham, P. Dobbin, R. Abeysinghe, 1993, British journal of haematology.

Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice.

R. Abeysinghe, R. Hider, E. Huehns, 1991, Blood.

Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.

R. Hider, E. Huehns, J. Porter, 1990, Blood.

ANIMAL TOXICOLOGY OF IRON CHELATOR L1

R. Abeysinghe, R. Hider, E. Huehns, 1989, The Lancet.

Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.

E. Huehns, J. Porter, V. Saez, 1988, Blood.

Selection of hydroxypyridin-4-ones for the treatment of iron overload using in vitro and in vivo models.

R. Hider, E. Huehns, J. Porter, 1988, Hemoglobin.

In vivo evaluation of hydroxypyridone iron chelators in a mouse model.

E. Huehns, J. Porter, R. Hider, 1987, Acta haematologica.

A direct method for quantification of non-transferrin-bound iron.

R. Hider, S. Singh, J. Porter, 1990, Analytical biochemistry.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

M. Cappellini, V. Viprakasit, R. Galanello, 2013, Annals of Hematology.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

Practical management of iron overload

J. Porter, 2001, British journal of haematology.

A Risk-Benefit Assessment of Iron-Chelation Therapy

John B. Porter, J. Porter, 1997, Drug safety.

Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds.

R. Abeysinghe, R. Hider, S. Singh, 1994, Advances in experimental medicine and biology.

Update on the hydroxypyridinone oral iron-chelating agents.

R. Hider, E. Huehns, J. Porter, 1990, Seminars in hematology.

Evaluation in vivo of hydroxypyrid-4-one iron chelators intended for the treatment of iron overload by the oral route

R. Hider, E. Huehns, J. Porter, 1986 .

Synthesis, Physicochemical Properties, and Biological Evaluation of N- Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential.

P. Dobbin, D. V. D. Helm, G. Xiao, 1994 .

Manuscript Title: Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with clinically established chelators. Running Title: The role of Eltrombopag in iron chelation Authors:

B. Psaila, Hider, J. Porter, 2019 .

Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform.

D. Swinkels, J. Hendriks, R. Hider, 2005, Analytical biochemistry.

INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA

Cappellini, R. Chopra, G. Graziadei, 2014 .

Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Non-β0/β0 Genotypes

F. Locatelli, A. Thrasher, A. Thompson, 2019, Blood.

Technical Report: Triple-Colour Staining Flow Cytometry for Co-Distribution of Thrombospondin Receptor (CD36), Ribonucleic Acid (RNA) and Fetal Haemoglobin (HbF) in Sickle Red Blood Cells

B. Davis, N. Bigelow, J. Porter, 2001, Hematology.

Flow cytometric method for simultaneous assay of foetal haemoglobin containing red cells, reticulocytes and foetal haemoglobin containing reticulocytes.

B. Davis, N. Bigelow, J. Porter, 2001, Clinical and laboratory haematology.

The metabolites of nitric oxide in sickle‐cell disease

D. Grimwade, D. Rees, J. Porter, 1995, British journal of haematology.

Why are hemoglobin F levels increased in HbE/beta thalassemia?

J. Clegg, D. Weatherall, D. Rees, 1999, Blood.

Simplified flow cytometric method for fetal hemoglobin containing red blood cells.

B. Davis, N. Bigelow, B H Davis, 2000, Cytometry.

Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease.

D. Linch, J. Porter, P. Roberts, 1998, Blood.

Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion

A. Qureshi, S. Pancham, S. Allard, 2017, British journal of haematology.

Sample acceptance time criteria, electronic issue and alloimmunisation in thalassaemia

J. Porter, M. Mcbrearty, S. Trompeter, 2015, Transfusion medicine.

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2020 .

Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients

F. Piel, S. Lugthart, R. Hollingsworth, 2020, Haematologica.

P1565: MITAPIVAT IMPROVES INEFFECTIVE ERYTHROPOIESIS AND REDUCES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

V. Beynon, H. Al‐Samkari, P. Kosinski, 2022, HemaSphere.

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY

V. Viprakasit, F. Galactéros, V. Beynon, 2021, HemaSphere.

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT

V. Viprakasit, F. Galactéros, H. Al‐Samkari, 2021, HemaSphere.

Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency

V. Beynon, H. Al‐Samkari, P. Kosinski, 2021, Blood.

A. Ganser, M. Cappellini, D. Bowden, 2012, Anemia.

Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia.

A. Schambach, T. Olson, P. Amrolia, 2021, The New England journal of medicine.

Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort

E. Neufeld, F. Trachtenberg, D. Kleinert, 2010, American journal of hematology/oncology.

Northstar-3: Interim Results from a Phase 3 Study Evaluating Lentiglobin Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia and Either a β0 or IVS-I-110 Mutation at Both Alleles of the HBB Gene

A. Kulozik, F. Locatelli, A. Thompson, 2019, Blood.

Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan

Dudley J Pennell, Taigang He, John-Paul Carpenter, 2014, Journal of Cardiovascular Magnetic Resonance.

Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials.

M. Cappellini, S. Fucharoen, F. Bonifazi, 2011, Blood cells, molecules & diseases.

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias

S. Perrotta, A. Taher, A. Kattamis, 2018, Health and Quality of Life Outcomes.

Lentiglobin Gene Therapy for Patients with Transfusion-Dependent β-Thalassemia (TDT): Results from the Phase 3 Northstar-2 and Northstar-3 Studies

A. Kulozik, F. Locatelli, A. Thrasher, 2018, Blood.

Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients with Non-β0/β0 Genotypes

F. Locatelli, A. Thrasher, A. Thompson, 2017 .

Relationship between the severity of β‐thalassaemia syndromes and the number of alleviating mutations

M. Petrou, J. Old, J. Porter, 1997, European journal of haematology.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders

D. Swinkels, G. Brittenham, J. Hendriks, 2016, Haematologica.

Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools

J. Porter, Kathryn P Hoyes, 1993, British journal of haematology.

Neutrophil Activation in Experimental Venous Hypertension

R. Abeysinghe, J. Scurr, P. Smith, 1993, Phlebologie.

Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study.

P. Coleridge-Smith, J. Scurr, J. Porter, 2000, Journal of vascular surgery.

The kinetics of unmatched and HLA‐matched 111In‐labelled homologous platelets in recipients with chronic marrow hypoplasia and anti‐platelet immunity

S. Lewis, A. Peters, E. Gordon-Smith, 1985, British journal of haematology.

Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminohexyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice.

S. Srichairatanakool, S. Fucharoen, Nittaya Chansiw, 2014, Asian Pacific journal of tropical medicine.

Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.

J. Vadolas, N. Chattipakorn, S. Srichairatanakool, 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

Endothelial activation in patients with chronic disease

J. Scurr, D. Shields, J. Porter, 1998 .

Blood Transfusion: Quality and Safety Issues in Thalassemia, Basic Requirements and New Trends

J. Porter, 2009, Hemoglobin.

Evaluation of new iron chelators for clinical use.

J. Porter, 1996, Acta haematologica.

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

E. Vichinsky, M. Cappellini, R. Galanello, 2009, British journal of haematology.

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

P. Brissot, M. Cappellini, Y. Deugnier, 2011, Gastroenterology.

The relationship between lipophilicity of hydroxypyrid-4-one iron chelators and cellular iron mobilization, using an hepatocyte culture model

R. Hider, E. Huehns, J. Porter, 1986 .

Increased leucocyte apoptosis in transfused β‐thalassaemia patients

B. Ames, E. Neufeld, F. Trachtenberg, 2013, British journal of haematology.

The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload.

A. Bagshaw, R. Abeysinghe, M. Farquharson, 2000, Physics in medicine and biology.

Deferasirox: An effective once-daily orally active iron chelator.

J. Porter, 2006, Drugs of today.

Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids.

R. Hider, S. Singh, J. Porter, 1990, Analytical biochemistry.

New insights into transfusion-related iron toxicity : implications for the 1 oncologist 2

M. Cappellini, T. D. de Witte, N. Gattermann, 2015 .

The toxic effects of desferrioxamine.

E. Huehns, J. Porter, 1989, Bailliere's clinical haematology.

Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents.

A. Curnow, A. Macrobert, S. Bown, 1998, British Journal of Cancer.

The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.

S. C. Chang, A. MacRobert, S. Bown, 1997, Journal of photochemistry and photobiology. B, Biology.

Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism.

E. Huehns, J. Porter, 1987, Acta haematologica.

Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

E. Neufeld, E. Vichinsky, N. Olivieri, 2008, Haematologica.

Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection.

R. Hider, S. Singh, J. Porter, 1992, Analytical biochemistry.

Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [HBA2: c.269A>T (or HBA1)] and α-Thalassemia: A Clinical Update

J. Porter, N. Huntley, Dana Warcel, 2016, Hemoglobin.

Secondary Erythrocytosis Due to Compound Homozygosity, but not Compound Heterozygosity, for Hb Luton and α-Thalassemia: A Family Study

C. Fisher, S. Khambadkone, A. Stephens, 2012, Hemoglobin.

Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro

M. Georgieff, J. Bussel, B. Psaila, 2021, Blood advances.

Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis

D. Girelli, N. Wood, A. Giorgetti, 2020, International journal of molecular sciences.

Recent Insights into Interactions of Deferoxamine with Cellular and Plasma Iron Pools: Implications for Clinical Use

S. Srichairatanakool, J. Porter, B. Davis, 2005, Annals of the New York Academy of Sciences.

Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemia

M. Lythgoe, A. David, T. Roberts, 2017, Scientific Reports.

Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World

P. Kellman, S. Piechnik, J. Moon, 2016, Circulation.

Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent β-Thalassemia

A. Kulozik, F. Locatelli, A. Thrasher, 2020 .

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

M. Cappellini, V. Viprakasit, A. Taher, 2015, British journal of haematology.

Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency

V. Viprakasit, F. Galactéros, M. Morado, 2020 .

Extracts of Thai Perilla frutescens nutlets attenuate tumour necrosis factor-α-activated generation of microparticles, ICAM-1 and IL-6 in human endothelial cells

S. Srichairatanakool, N. Utama‐ang, C. Uthaipibull, 2020, Bioscience reports.

Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload

D. Pennell, W. Banya, T. He, 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron

D. Pennell, L. Anderson, M. Westwood, 2007, Journal of magnetic resonance imaging : JMRI.

Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network

E. Neufeld, F. Trachtenberg, E. Vichinsky, 2012 .

Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay

S. Srichairatanakool, S. Fucharoen, R. Hider, 2016, Translational research : the journal of laboratory and clinical medicine.

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

M. Cappellini, V. Viprakasit, T. Coates, 2020 .

Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults

K. Kowdley, A. Taher, L. Chawla, 2018, Blood.

Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade®): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.

M. Cappellini, A. Taher, G. Forni, 2008 .

Iron Chelation in Regularly Transfused Patients with Aplastic Anemia: Efficacy and Safety Results from the Large Deferasirox EPIC Trial

A. Ganser, Zhi-xiang Shen, Sung-Soo Yoon, 2008 .

Efficacy and Safety of Deferasirox (Exjade®) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, A. Taher, A. El‐Beshlawy, 2008 .

Efficacy and Safety of Deferasirox (Exjade®) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

D. Pennell, M. Cappellini, Chi-kong Li, 2008 .

Deferasirox Efficacy and Safety for the Treatment of Transfusion-Dependent Iron Overload in Patients with a Range of Rare Anemias.

S. Thein, A. Hmissi, J. Porter, 2008 .

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

D. Pennell, M. Tanner, J. Porter, 2008 .

Long-Term Treatment with Deferasirox (Exjade®, ICL670), a Once-Daily Oral Iron Chelator, Is Effective in Patients with Transfusion-Dependent Anemias.

E. Vichinsky, M. Cappellini, R. Galanello, 2007 .

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.

M. Cappellini, V. Viprakasit, A. Taher, 2014, Blood cells, molecules & diseases.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

S. Perrotta, M. Cappellini, V. Viprakasit, 2013 .

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

M. Cappellini, V. Viprakasit, R. Galanello, 2012 .

Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study

V. Viprakasit, R. Galanello, A. Taher, 2012 .

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

E. Neufeld, H. Rienhoff, E. Vichinsky, 2011 .

Calibration of Improved T2*Method for the Estimation of Liver Iron Concentration in Transfusional Iron Overload

D. Pennell, Gillian Smith, J. Carpenter, 2009 .

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion-Dependent Thalassemia

E. Vichinsky, A. Lal, P. Harmatz, 2009 .

Effect of green tea on iron status and oxidative stress in iron-loaded rats.

S. Srichairatanakool, S. Fucharoen, J. Porter, 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS

M. Cappellini, V. Viprakasit, R. Galanello, 2013 .

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

M. Cappellini, V. Viprakasit, R. Galanello, 2011 .

E. Neufeld, M. Cappellini, V. Viprakasit, 2020 .

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2019, Blood.

Secondary hemochromatosis in Bthalassemia and sickle cell disease

John B. Porter, E Vichinsky, Paul Harmatz, 2002 .

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

D. Pennell, A. Piga, A. El‐Beshlawy, 2013 .

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

R. Chopra, O. Hermine, F. Galactéros, 2013 .

EFFICACY AND SAFETY OF DEFERASIROX IN PATIENTS WITH BASELINE LIVER IRON CONCENTRATION (LIC) < 7 OR=7 MG FE/G DW: RESULTS OF EPIC LIVER MAGNETIC RESONANCE IMAGING (MRI) SUBSTUDY

A. Taher, A. El‐Beshlawy, Mohsen Saleh Elalfy, 2010 .

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Efficacy and Safety of Once-Daily, Oral Iron Chelator Deferasirox (Exjade ® ) in a Large Group of Regularly Transfused Patients with β-Thalassemia Major

M. Cappellini, A. Taher, Mohsen Saleh Elalfy, 2008 .

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade®)

A. Ganser, M. Cappellini, D. Bowden, 2008 .

A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry.

U. Schaible, M. Podinovskaia, R. Hider, 2014, The Biochemical journal.

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

J. Porter, Y. Aydinok, P. Evans, 2012, Haematologica.

Influence of patient‐reported outcomes on the treatment effect of deferasirox film‐coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis

S. Perrotta, A. Taher, M. Duh, 2019, American journal of hematology.

Predicting serum ferritin levels in patients with iron overload treated with the film‐coated tablet of deferasirox during the ECLIPSE study

A. Taher, S. Weber, J. Porter, 2018, American journal of hematology.

CONTINUED IMPROVEMENT IN CARDIAC T2*WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Combined Chelation Therapy with Deferasirox and Deferoxamine In Transfusion Dependent Thalassemia

E. Vichinsky, A. Lal, P. Harmatz, 2010 .

Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.

D. Pennell, L. Anderson, M. Westwood, 2005 .

Soluble Markers of Leucocyte Adhesion in Patients with Venous Disease

J. Scurr, P. Smith, D. Shields, 1997 .

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

D. Pennell, M. Cappellini, Chi-kong Li, 2009 .

Efficacy and safety of deferasirox (Exjade®) in patients with β-thalassemia major treated for up to 5 years

S. Perrotta, M. Cappellini, A. Piga, 2009 .

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

P. Marks, O. Onyekwere, P. Swerdlow, 2005 .

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

S. Perrotta, A. Taher, A. Kattamis, 2016 .

Calibration of myocardial T2 and T1 against iron concentration

M. Sheppard, D. Pennell, D. Firmin, 2014, Journal of Cardiovascular Magnetic Resonance.

Changes In Health Status and Quality of Life In Adults with Thalassemia Year 1 Report of the Thalassemia Longitudinal Cohort Study

E. Neufeld, F. Trachtenberg, D. Kleinert, 2010 .

Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.

M. Cappellini, V. Viprakasit, A. Taher, 2009 .

Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.

S. Srichairatanakool, S. Fucharoen, J. Porter, 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

Safety of deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload : a pooled analysis focusing on renal function

P. Greenberg, M. Cappellini, M. Schmid, 2009 .

Deferiprone Is Associated with Lower Serum Ferritin (SF) Relative to Liver Iron Concentration (LIC) Than Deferoxamine and Deferasirox- Implications for Clinical Practice

Farrukh T Shah, J. Porter, Ai Leen Ang, 2010 .

INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA

Cappellini, R. Chopra, G. Graziadei, 2015 .

The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron‐carbohydrate administration

I. Cabantchik, J. Porter, C. Hershko, 2022, American journal of hematology.

Response to Cabantchik and Hershko commentary “Plasma nontransferrin bound iron–nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation”

J. Porter, M. Garbowski, R. Hider, 2021, American journal of hematology.

Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (Exjade®, ICL670).

J. Ford, M. Cappellini, A. Cohen, 2007 .

A Trial to Investigate the Relationship between DFO Pharmacokinetics and Metabolism and DFO‐Related Toxicity

C. Howes, J. Porter, L. Brookman, 1998, Annals of the New York Academy of Sciences.

Inhibition of iron-containing metalloenzymes by 3-hydroxypyridin-4-one chelators

R. Hider, R. Kayyali, J. Porter, 1997 .

In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.

R. Abeysinghe, R. Hider, J. Porter, 1993, Experimental hematology.

Coronary artery bypass graft surgery in a patient with haemoglobin SC disease

J. Porter, W. Marchant, S. Wright, 2001, Anaesthesia.

Secretion of neutrophil secondary granules occurs during granulocyte‐macrophage colony stimulating factor induced margination

R. Abeysinghe, D. Linch, S. Devereux, 1990, British journal of haematology.

Neutrophil CD11b Expression in Patients with Venous Disease

J. Scurr, D. Shields, P. C. Smith, 1996 .

Plasma Lactoferrin as a Marker of White Cell Degranulation in Venous Disease

R. Abeysinghe, J. Scurr, P. Smith, 1994 .

CD11b/CD18 as a Marker of Neutrophil Adhesion in Experimental Venous Hypertension

J. Scurr, D. Shields, J. Porter, 1995 .

Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia

Jane Vosper, Farrukh T Shah, J. Porter, 2018, Hemoglobin.

SLN124, a GalNAc Conjugated 19-Mer Double-Stranded SiRNA Reduces Iron and Increases Hepcidin Levels of Healthy Volunteers in a Phase 1 Clinical Study

A. Scrimgeour, M. Muckenthaler, L. James, 2021, Blood.

Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice.

S. Srichairatanakool, S. Fucharoen, J. Porter, 2009, Medicinal chemistry.

Application of 1,2-diethyl-3-hydroxypyridin-4-one to enhance tissue selectivity for photodynamic therapy of the bladder

Alexander J. MacRobert, Stephen G. Bown, Shi-Chung Chang, 1994, Other Conferences.

Lactoferrin Release in Experimental Venous Hypertension

R. Abeysinghe, J. Scurr, D. Shields, 1995 .

Markers of Neutrophil Degranulation in Patients with Venous Disease

R. Abeysinghe, J. Scurr, S. Sarin, 1995 .

High index of suspicion for early diagnosis of alendronate‐induced stage zero osteonecrosis of jaw in thalassaemia major

S. Fedele, Farrukh T Shah, R. Bajoria, 2014, British journal of haematology.

Acute i.v. Methadone Kinetics in Man: relationship to chronic studies.

R. Moore, H. McQuay, R. Bullingham, 1982, British journal of anaesthesia.

Practice guidelines: lower extremity revascularization.

J. Deweese, J. Porter, R. Leather, 1993, Journal of vascular surgery.

SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers

A. Scrimgeour, M. Aleku, M. Muckenthaler, 2023, American journal of hematology.

Iron Trafficking and Distribution in Transfusional Overload: Insights From Comparing Diamond Blackfan Anemia with Sickle Cell Disease and Thalassemia

Jeffery L. Miller, E. Vichinsky, J. Meerpohl, 2012 .

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.